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Background: The opportunities for developing new drugs and vaccines for malaria control look brighter now than ten
years ago. However, there are few places in sub-Saharan Africa with the necessary infrastructure and expertise to support
such research in compliance to international standards of clinical research (ICH-GCP). The Clinical Research Unit of
Nanoro (CRUN) was founded in 2008 to provide a much-needed GCP-compliant clinical trial platform for an imminent
large-scale Phase 3 malaria vaccine trial. A dynamic approach was used that entailed developing the required
infrastructure and human resources, while engaging local communities in the process as key stakeholders. This
provided a better understanding and ownership of the research activities by the local population.
Case description: Within five years (2008–2013), the CRUN set up a fully and well-equipped GCP-compliant clinical
trial research facility, which enabled to attract 25 grants. The research team grew from ten health workers prior to 2008
to 254 in 2013. A Health and Demographic Surveillance System (HDSS), which covers a total population of about
60,000 people in 24 villages was set up in the district. The local community contributed to the development of
the facility through the leadership of the king and the mayor of Nanoro. As a result of their active advocacy, the
government extended the national electrical grid to the new research center, and later to the entire village. This
produced a positive impact on the community’s quality of life. The quality of health care improved substantially,
due to the creation of more elaborate clinical laboratory services and the acquisition of state-of-the-art equipment.
Conclusion: Involving the community in the key steps of establishing the centre provided the foundation for what
was to become the CRUN success story. This experience demonstrates that when clinical trials research sites are
carefully developed and implemented, they can have a positive and powerful impact on local communities in
resource-poor settings, well beyond the task of generating expected study data.Background
The epidemiology of malaria in sub-Saharan Africa is
changing, with a decline in malaria-attributed deaths
[1]. This is largely due to a significant increase in the
financial commitment to the battle against malaria,
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are currently available to the malaria research community,
the opportunities for the development of new drugs
and vaccines for malaria control look brighter now than
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tual elimination of malaria. Despite reports of dramatic
declines in the burden of malaria in a number of countries
[3], it remains stubbornly high in many areas, such as
Burkina Faso. Elsewhere, a decline in malaria was followed
by its reintroduction due to close proximity to areas of
appreciable transmission [4]. In this context, it is extremely
important to establish the safety, efficacy, and effectiveness
of new interventions [2]. Yet, there are few places in
sub-Saharan Africa with the necessary infrastructure
and expertise to conduct such research in accordance
to international standards (ICH-GCP). Moreover, very few
African research centres have been able to maintain the
required infrastructure and expertise over time, despite
having conducted GCP-compliant clinical trials in the
past. One reason is that the subsistence of the centres is
often linked to one or only a few specific projects, which
are time-bound and resource-limited. Once a specific
project ends, experienced staff cannot be maintained. A
number of centres in the region operate as field sites for
Northern institutions. Therefore, they lack the leverage of
autonomy to drive a local agenda and development plan.
Such circumstances have major impacts on the ability of
truly African centres, with competent local investigators,
to compete for international funds. Nevertheless, it should
be recognized that in the most recent years this is chan-
ging. In fact, some of African key senior scientists through
some initiatives, such as the European and Developing
Countries Trial Partnership (EDCTP) are becoming part
of the main drivers of the research agenda.
There is a clear need to establish sustainable clinical
research centres operating in accordance to international
standards for the timely evaluation of new products and
interventions [5]. This recognition led to the creation of
the Clinical Research Unit of Nanoro (CRUN), which today
provides a ready platform for testing new interventions in
the environment where eventually they may be deployed.
The CRUN is jointly run by two Burkinabe medical re-
search institutions—namely the Centre Muraz (CM)
and the Institut de Recherche en Sciences de la Santé
(IRSS)—in collaboration with the Saint Camille Medical
Center of Nanoro (CMA), which is a referral hospital for
the District of Nanoro and is run by an Italian religious
order in partnership with the government. The team was
able to set-up a high-quality platform fully compliant with
international standards for training and research and a
Health and Demographic Surveillance System (HDSS) of
about 60,000 people. To establish this capacity, CRUN
leaders used a dynamic approach that engaged the local
community throughout the process.
The birth of CRUN
CRUN has been established by researchers from Centre
Muraz and Institut de Recherche en Sciences de la Santé(IRSS), the two leading health researcher institutes in
Burkina Faso. Centre Muraz (CM) entered into the
malaria research field in 1985, when it implemented the
continuous surveillance of malaria drug resistance in
Burkina Faso. In the years that followed, this activity
was carried out by CM in collaboration with IRSS and
the National Malaria Control Programme (NMCP), after
the creation of the latter in 1990 [6]. In 1998, the NMCP
stratified the country into three zones according to their
malaria transmission pattern (Figure 1). In each zone, two
sentinel sites were established for the epidemiological
surveillance of anti-malarial drug resistance in the frame-
work of the Roll Back Malaria initiative [7]. The village of
Nanoro was one of the two sentinel sites chosen in the
central area. The health district of Nanoro is one of the
five districts of centre-west health region. It is situated at
approximately 90 Km from Ouagadougou, the capital city.
In 2013, the total population was estimated at 158,127
people (data from the National Institute of Statistics and
Demography). The population growth rate is 3.06% (2013
estimate). Mossi represent the main ethnic group, with the
remaining represented by Gurunsi and Fulani. About 90%
of the population is engaged in subsistence agriculture,
which is vulnerable to periodic droughts. The literacy
rate is low in both men and women (about 23%). The
epidemiological profile of diseases remains dominated
by communicable infectious diseases. The inadequacy of
drinking water, individual and collective hygiene, associ-
ated to poverty is the main reasons of health problems.
The general morbidity is high and malaria accounts for
about 40% of the total burden of diseases. Maternal
mortality rate is 300 deaths/100,000 live births (2010)
and infant mortality rate is 78.3 deaths/1,000 live births.
Malaria represents a significant burden on the population,
but especially pregnant women and children; it is the first
cause of consultation (35.12%), hospitalization (40.83%)
and death (37.5%) (Ministry of Health [MoH]). As sentinel
site, epidemiological studies on malaria were conducted in
Nanoro beginning in 1998, including regular assessment
of drug resistance. These studies were only carried out
during the rainy season (six months per year). The sentinel
site of Nanoro attracted more interest during 20012004,
when resistance to chloroquine (at that time, the recom-
mended first line treatment of uncomplicated malaria)
emerged for the first time in the area. The data generated
from these studies provided evidence that led the NMCP
to change the national malaria treatment policy in 2005,
from chloroquine to artemisinin-based combination ther-
apy(ACT), namely artesunate-amodiaquine (ASAQ) and
arthemeter-lumefantrine (AL) [8]. During this period, the
research team did not reside in Nanoro, instead the team
members regularly travelled to Nanoro to collect data and
then returned to their respective institutions at the end
of each study. With the historic detection of chloroquine
Figure 1 Map of Burkina Faso showing Nanoro and the three malaria transmission zones.
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need to establish more clinical research centres in Africa,
the CRUN leaders proposed to establish a permanent
team and facility in Nanoro. The proposal benefited from
a favourable context of increasing political and financial
support for malaria research. Although the site was disad-
vantaged by not being on the national electrical grid, the
research team could successfully conduct its first clinical
trial at ICH-GCP standards on ACT in 2005 [9]. In 2007,
a second study on ACT, funded by the European and
Developing Countries Partnership (EDCTP), was suc-
cessfully conducted [10]. Based on this experience, the
CRUN was selected in 2007 to be part of the RTS, S
phase III malaria vaccine trial, a multicentre study at 11
centers in seven African countries [11]. As a major research
contributor to the study, the CRUN joined the Malaria
Clinical Trial Alliance (MCTA) network [5]. Technical
support teams from MCTA in partnership with the PATH
Malaria Vaccine Initiative (MVI) and GlaxoSmithKline
(GSK Biologicals) visited the CRUN and identified the
support required to execute the RTS,S phase III trial at
Nanoro. The site was awarded infrastructure capacity
enhancement grants by MCTA in 2007 and 2008 to refur-
bish the settings and upgrade the equipment. This support
proved crucial for the successful execution of the RTS,S
trial, and enhanced the site’s ability to conduct other trials
to ICH-GCP standards. This track record led to the
full establishment of the CRUN in 2008, followed by
the inauguration of its new facility in April 2009 by the
Minister of Health. A Health and Demographic Surveil-
lance System (HDSS) was set up in the district. It covers atotal population of about 60,000 people in 24 villages [12].
The HDSS was implemented according to INDEPTH
guidelines, with regular surveys every four months and
continuous monitoring by village reporters. This was en-
abled by being associate members of INDEPTH-Network.
The CRUN researchers were able to access the INDEPTH
resource materials and visit other INDEPTH member
HDSS sites, while scientists from other HDSS sites on the
network visited CRUN for technical support. The HDSS
has become the bedrock of the CRUN research activities
because it allows the identification, selection, and follow-
up of study participants, as well as the monitoring of
population and disease dynamics. CRUN is now a full
member of the INDEPTH network and able to contrib-
ute datasets for joint analysis. This initiative was also
supported by the Belgium cooperation through the Insti-
tute of Tropical Medicine (ITM) Framework Agreement 3
(FA3: 2008–2013), which has served as the main source of
operational and training support since 2008.
The main objective of establishing the CRUN was to
develop and maintain an appropriate expertise and infra-
structure ensuring high quality clinical research and train-
ing. The vision of the CRUN is to become a prominent
research and training centre in sub-Saharan Africa, to
participate in the formulation of African public health
strategies and programs, and to provide competent expert-
ise in the health field. The CRUN’s mission is to provide
evidence-based information for the health care of popula-
tions living in tropical countries, with a specific focus on
malaria. This will be achieved by providing an excellent
platform for training and research in tropical diseases
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platform could be offered to address some specific
research questions relevant to the MoH local agenda
and development plan. In fact, having the Centre Muraz
as partner in this initiative gives the opportunity to the
CRUN to have a link with the MoH stakeholders such
as the National Programs, including the malaria control
programme and the national drug regulatory author-
ities, helping in the translation of research findings into
practice.
Organization and management
The two institutions (CM and IRSS) collaborating to run
the CRUN are both located in Bobo-Dioulasso in the
south-west of Burkina Faso. They are closely linked in
and have been working together for the last 20 years.
The CM is under the auspices of the Ministry of Health,
while the IRSS is housed in the Ministry of Research and
Innovation. The CM/IRSS is the largest medical research
group in Burkina Faso and among the largest in the
West African Francophone countries. The team’s scientific
interest is mainly malaria research, but studies on other
parasitic diseases (helminthiasis, filariasis, schistosomiasis)
have been conducted. The team provides also support for
training health practitioners (MD, PharmD, Msc, PhD)
in collaboration with national universities (Ouagadougou
and Bobo-Dioulasso). The linkage to academic institutions
is a great asset as it provides a pathway for career de-
velopment, sustainable career progression, and reliable
availability of younger scientists.
At the inception of the research activities in Nanoro,
the CRUN management structure was project oriented,
i.e., each project had its own leader and team, with little
coordination among the different projects. However, this
changed in 2010 with the introduction of a more transver-
sal organization across the different projects. The CRUN
has been organized in five sections: laboratory, clinical
activities, IT & data management, Health & Demographic
Surveillance System (HDSS), and pharmacy, each with a
designated manager.
Achievements
Infrastructure refurbishment and equipment upgrades
Before the grants provided by MCTA (2005–2008), the
CRUN was hosted by the CMA of Nanoro and research
activities were conducted within the hospital complex. A
small clinical ward was dedicated to clinical trial activities,
while the laboratory facility was shared with the hospital.
In 2009, the site constructed a new clinical trial facility,
which was funded by MCTA, and where most of its
research activities was transferred to. A fully functioning
clinical laboratory (parasitology, biochemistry, haematol-
ogy, microbiology and blood/cells culture) has been set up
with the new equipment, including back-up equipment toensure reliable services. The government of Burkina Faso,
in recognizing the national interest in clinical research for
a vaccine and other malaria interventions, extended the
national electrical grid to the trial site and the village of
Nanoro. Providing reliable electricity has proven to be a
great achievement for this challenging initiative. Through-
out the development of CRUN, the leadership of MCTA
remained engaged, providing invaluable technical and
mentorship support. A grant was provided in 2008 by the
Belgium Cooperation through the Institute of Tropical
Medicine Framework Agreement 3 (ITM FA3) was also
of significant help. Although modest compared to MCTA
funds, it provided support for three PhD grants and thus,
contributed to creating a core group of young scientists
able to attract additional new grants.
Research activities and grants obtained
Before CRUN was fully established, the site was only able
to conduct two studies from 2005 to 2008. After obtaining
the grants from MCTA in 2007 and 2008, and later with
the grant from the Belgium cooperation (FA3), the centre
was able to attract 25 grants from 2008 to 2013 (Tables 1
and 2). Similarly, the number of staff working at the
CRUN increased from 10 people before 2008 to 254
people in 2013. This was possible due to the quality of
the physical infrastructure and equipment available.
Support from MCTA and MVI to set up a rigorous
quality management system has also contributed to the
success of the centre.
CRUN’s enhanced infrastructure has enabled the centre
to network with other research and academic centres,
for example, by hosting two international GCP courses
in 2010 and 2012, supported by Belgium Cooperation
and the Institute of Tropical Medicine (ITM) Clinical
Trial Strategic Network activities. The two courses brought
together 34 participants from four different geographical
areas (East and West Africa, Southeast Asia and Latin
America) [13]. The course had a very innovative approach,
consisting of theory, case studies and a practical segment
in the field. Having participants from different geographical
areas provided a dynamic experience as the participants
examined clinical research challenges from diverse regions
in a complementary manner.
Impact of the CRUN establishment on the community
In the literature, few studies have been conducted to
address the impact of clinical trials and clinical trial plat-
forms on trial participants, their families and communities
[14-16]. Lessons learnt from these reports indicate that
clinical trials, especially when conducted in resource-poor
settings, may negatively impact the quality of health care,
e.g., by diverting resources from routine clinical activities,
brain-drain among the best qualified health staff, dis-
crimination of enrolled versus non-enrolled persons, or
Table 1 List of research projects grants awarded since the CRUN establishment in 2008
Year Title of the study/activity funded Funder
2008
Pharmacovigilance for Artemisinin-based combination treatments in Africa World Health Organization/(WHO/TDR)
Multi-drug resistance in malaria under combination therapy Assessment of specific
markers and development of innovative, rapid and simple diagnostics (MALACTRES)
European Union (FP7)
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women with Plasmodium
falciparum infection
Malaria in Pregnancy (MiP) Consortium
A Phase II multicenter, efficacy and safety study of parenteral SAR97276A Sanofi Aventis
2009
Safe and efficacious artemisinin-based combination treatments for African pregnant
women with malaria
European and Developing Countries
Partnership (EDCTP)
Efficacy of GSK Biologicals. candidate malaria vaccine (257049)against malaria disease
caused by P. falciparum infection in infants and children in Africa
Malaria Vaccine Initiative (MVI)
Parallel group, double-blind, randomized study assessing the efficacy, safety and
pharmacokinetic profile of ferroquine associated with artesunate
Sanofi aventis
2010
Assessment of the Safety of Anti-malarial Drug Use During Early Pregnancy Malaria in Pregnancy (MiP) Consortium
Malaria risk prior to and during early pregnancy in nulliparous women receiving
long-term weekly iron and folic acid supplementation
National Institute of Health (NIH)
Epidemiology study of malaria transmission intensity in sub-Saharan Africa Malaria Vaccine Initiative (MVI)
Study of immune correlates of protection against malaria after vaccination with RTS, S/AS01E Malaria Vaccine Initiative (MVI)




Site characterization as a prelude to a study of malaria elimination using a combination
of malaria control strategies in the Sahel region of Burkina Faso
Malaria Capacity Development
Consortium (MCDC)
Phase III randomized, open, controlled study to evaluate the immune response to the
hepatitis B antigen of the RTS,S/AS01E candidate vaccine
GlaxoSmithKline (GSK) Biologicals
Improved quality of diagnostic services for malaria in pregnancy World Health Organization/(WHO/TDR)
2012
Severe malaria and invasive bacterial disease among children: proportions, incidence
rates and diagnostic value of Malaria Rapid Diagnostic Tests (ongoing)
Institute of Tropical Medicine (Belgium
Cooperation)
Community-based scheduled screening and treatment of malaria in pregnancy for improved
maternal and infant health: a cluster-randomized trial in The Gambia, Burkina Faso and Benin
European Union (EU FP7)
Genomic and environmental risk factors for cardio-metabolic disease in Africans. National Institute of Health (NIH)
2013
Study of the Incidence, Reservoir and Routes of Transmission of Invasive Salmonellosis in
Burkina Faso (IRTIS -BF)
Institute of tropical medicine
(Belgium Cooperation)
An open-label, single-arm study to evaluate the efficacy, safety and PK of Artemether-Lumefantrine
dispersible tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in
infants <5 kg body weight
Novartis
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of a
new paediatric eurartesim dispersible formulation and crushed film coated eurartesim tablet,
in infant patients with Plasmodium falciparum malaria
Sigma Tau
Observational study to evaluate the clinical safety after introduction of the fixed-dose Artemisinin-based
Combination Therapy Eurartesim® (dihydroartemisinin/piperaquine [DHA/PQP]) in public health districts
in Burkina Faso, Mozambique, Ghana and Tanzania
Indepth network
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The clinical trial may also have a negative impact on the
relationship between a health facility and the community;
for instance, in cases of poor or inappropriate communi-
cation about the nature and the objectives of the research
or a lack of knowledge about local culture and customs byTable 2 List of other activities’ grants awarded since the CRU
Year Title of the study/activity funded
2008
Grant to support the establishment of Malaria Clinical Researc
Support for the establishment of a Pharmacovigilance system
2010 Good Clinical Practice: a theoretical and practical training in Bresearchers. Conversely, clinical trials can contribute to
the quality of routine healthcare and thus the wellbeing
of a community, either directly (additional training of
health staff and structural upgrades of health facilities)
or indirectly (improved access to healthcare that improves
the quality of routine healthcare [17].N establishment in 2008
Funder
h Unit in Burkina Faso Belgian cooperation
for ACT safety monitoring in Burkina Faso Sanofi aventis
urkina Faso Belgian cooperation
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pact of the CRUN on the Nanoro community; however,
the interactive approach led by local researchers obviated
the negative perceptions and lack of understanding about
the intentions and conduct of CRUN’s research activities.
Researchers involved the community (district health
management, elders, chief, and opinion leaders) in the
founding steps of establishing the CRUN. To make the
community a real partner in the centre’s activities, a
tacit agreement was made that priority would be given
to local people, in a competitive manner, for all non-
professional jobs (construction workers, drivers, cleaners,
field workers, data clerks, and others). Of the 254 people
employed at the CRUN, about one-third come from
Nanoro. This has strengthened the sense of ownership
of the centre’s activities by the community. Through the
modest creation of new jobs, CRUN makes a substantial
contribution to reducing poverty in the community. In
addition, staff members residing in Nanoro contribute to
the micro-economy there.
Another crucial benefit for Nanoro and CRUN stemming
from their productive engagement was electrification for
the area. This was made possible by the mayor of Nanoro
leading the negotiations for extending the national electrical
grid to the CRUN, and with it, to the village of Nanoro.
Electrification spurred a lot of economic activity and social
amenities that enhance the wellbeing of the community,
such as: (1) improved water supply through use electricity
instead of generator; (2) ability to use electrical devices,
such as fans during the hot season (when temperatures can
reach 45-47°C), lighting so students can study at night, the
use of refrigeration to safely store food and the extension of
business hours past sunset.
Health care services have been improved through
CRUN’s new microbiology laboratory. Before this la-
boratory was established, local patients had to travel
about 100 km to the capital city, Ouagadougou, for the
service. In addition, putting the local hospital on the
electrical grid improved the working conditions of the
health professionals, notably the ability to conduct surgery
24 hours a day and optimal storage of EPI vaccines at
district health facilities. Last, but not least, in terms of
benefits, is the installation of digital X-ray equipment (the
first in Burkina Faso), which is now used for all patients
attending the hospital regardless of their participation in
the clinical trials.
Conclusion
The innovative interactive approach to developing the
CRUN based on active engagement with the community,
have been central to establishing the centre and providing
the foundation for the CRUN success story. Aside from
the positive impact of the infrastructure upgrade on the
standard of health care services, the electrification ofthe trial site positively impacted the quality of life in
the community. This demonstrates that strong positive
advocacy can lead African governments to take on more
responsibility in supporting research activities. However
the main challenge for CRUN in the future will be to
secure and strengthen the capacity established. For that,
the CRUN future strategic development plans should take
into account the “epidemiological transition” of malaria
with the decline of the number of clinical cases in endemic
countries and the concomitant need for research in other
endemic diseases. Therefore, beside malaria, currently the
main research subject, the activity of the unit should be
gradually expanded to other diseases, such as invasive
bacterial infections, tuberculosis, HIV, reproductive health,
schistosomiasis and other neglected diseases. In addition,
the HDSS platform which is so far mainly used for
research activities should be more and more used to
guide the district health management team. Indeed, the
HDSS by providing reliable health information such as
burden of disease profiles will contribute to a better
evaluation of health interventions by the Nanoro Health
District. The success story of the CRUN establishment
demonstrates that the impact of clinical trials on the com-
munity can be highly positive in resource-poor settings if
the concerned community is involved in the process.
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